The Analyst & Rating
UBS analyst Marc Goodman downgraded shares of Mallinckrodt from Buy to Neutral and lowered its 12-month price target from $70 to $24, a 66 percent downward revision.
Acthar volumes could come under pressure, contrary to previous expectations that it would continue to grow, Goodman said in a note. Going by the management's recent comments on Acthar, Goodman is not as optimistic as before.
The analyst made changes to his Acthar model, estimating declining volume, even as market share and pricing assumptions were left unchanged. This along with lower INOmax sales for potential Praxair, Inc. (NYSE: PX) competition, has led the analyst to significantly reduce his valuation.
UBS is moving to the sidelines at current levels until it has more visibility on Acthar volumes, INOmax competition, generics stability and pipeline. The firm lowered its earnings per share estimates for 2017 from $7.40 to $7.15 and that for 2016 from $8.15 to $7.15, assuming among other things, a 14 percent year-over-year drop in Acthar sales.
At time of writing, shares of Mallinckrodt were down less than 1 percent at $21.62. The stock is down 56 percent in 2017.
Here's Why Barclays Downgraded Mallinckrodt
Analyst: Nektar Has A Handful Of Milestones Ahead In 2018
Latest Ratings for MNK
|Nov 2017||Canaccord Genuity||Maintains||Hold|
|Nov 2017||Morgan Stanley||Maintains||Equal-Weight|
View More Analyst Ratings for MNK
View the Latest Analyst Ratings
See more from Benzinga
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.